Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease

Jill Roberts Center Study Group Study Group; Weill Cornell Medicine-Gastrointestinal Study Group

doi:10.1053/j.gastro.2020.05.066

Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease

Jill Roberts Center Study Group Study Group, Weill Cornell Medicine-Gastrointestinal Study Group

Research output: Contribution to journal › Article › peer-review

89 Scopus citations

Original language	English
Pages (from-to)	1541-1544.e2
Journal	Gastroenterology
Volume	159
Issue number	4
DOIs	https://doi.org/10.1053/j.gastro.2020.05.066
State	Published - Oct 2020
Externally published	Yes

Keywords

Biologic Therapy
COVID-19
IBD
SARS-CoV-2

Access to Document

10.1053/j.gastro.2020.05.066

Cite this

@article{74f836cd97f44ac0991f0a3947732b7e,

title = "Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease",

keywords = "Biologic Therapy, COVID-19, IBD, SARS-CoV-2",

author = "{Jill Roberts Center Study Group Study Group} and {Weill Cornell Medicine-Gastrointestinal Study Group} and Lukin, {Dana J.} and Anand Kumar and Kaveh Hajifathalian and Sharaiha, {Reem Z.} and Scherl, {Ellen J.} and Longman, {Randy S.} and Gabriela Funez-dePagnier and Lucia Duenas-Bianchi and Vinita Jacob and Battat, {Robert J.} and Tibor Krisko and Fortune, {Brett E.}",

note = "Funding Information: Conflicts of interest These authors disclose the following: D. J. Lukin received consulting fees from AbbVie, Abgenomics, Pfizer, Prometheus, and Takeda, and grant support from AbbVie and Takeda. E. J. Scherl received grant support from AbbVie, AstraZeneca, Crohn's and Colitis Foundation, Janssen, New York Crohn's Foundation, Pfizer, UCB, Genentech, Seres Therapeutics, and Celgene, consulting fees from AbbVie, Abgenomics, Crohn's and Colitis Foundation, Evidera, GI Health Foundation, Janssen, Protagonist, Seres, Takedal, stock from Gilead, and speaker for GI Health Foundation, Prime Therapeutics, and Janssen. R. S. Longman received grant support from Boehringer Ingelheim and consulting fees from Takeda, Pfizer, and Ancilla. The remaining authors disclose no conflicts. Funding Information: Conflicts of interest These authors disclose the following: D. J. Lukin received consulting fees from AbbVie, Abgenomics, Pfizer, Prometheus, and Takeda, and grant support from AbbVie and Takeda . E. J. Scherl received grant support from AbbVie , AstraZeneca , Crohn{\textquoteright}s and Colitis Foundation , Janssen , New York Crohn{\textquoteright}s Foundation , Pfizer , UCB, Genentech , Seres Therapeutics, and Celgene , consulting fees from AbbVie, Abgenomics, Crohn{\textquoteright}s and Colitis Foundation, Evidera, GI Health Foundation, Janssen, Protagonist, Seres, Takedal, stock from Gilead, and speaker for GI Health Foundation, Prime Therapeutics, and Janssen. R. S. Longman received grant support from Boehringer Ingelheim and consulting fees from Takeda, Pfizer, and Ancilla. The remaining authors disclose no conflicts. ",

year = "2020",

month = oct,

doi = "10.1053/j.gastro.2020.05.066",

language = "English",

volume = "159",

pages = "1541--1544.e2",

journal = "Gastroenterology",

issn = "0016-5085",

publisher = "W.B. Saunders",

number = "4",

}

TY - JOUR

T1 - Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease

AU - Jill Roberts Center Study Group Study Group

AU - Weill Cornell Medicine-Gastrointestinal Study Group

AU - Lukin, Dana J.

AU - Kumar, Anand

AU - Hajifathalian, Kaveh

AU - Sharaiha, Reem Z.

AU - Scherl, Ellen J.

AU - Longman, Randy S.

AU - Funez-dePagnier, Gabriela

AU - Duenas-Bianchi, Lucia

AU - Jacob, Vinita

AU - Battat, Robert J.

AU - Krisko, Tibor

AU - Fortune, Brett E.

N1 - Funding Information: Conflicts of interest These authors disclose the following: D. J. Lukin received consulting fees from AbbVie, Abgenomics, Pfizer, Prometheus, and Takeda, and grant support from AbbVie and Takeda. E. J. Scherl received grant support from AbbVie, AstraZeneca, Crohn's and Colitis Foundation, Janssen, New York Crohn's Foundation, Pfizer, UCB, Genentech, Seres Therapeutics, and Celgene, consulting fees from AbbVie, Abgenomics, Crohn's and Colitis Foundation, Evidera, GI Health Foundation, Janssen, Protagonist, Seres, Takedal, stock from Gilead, and speaker for GI Health Foundation, Prime Therapeutics, and Janssen. R. S. Longman received grant support from Boehringer Ingelheim and consulting fees from Takeda, Pfizer, and Ancilla. The remaining authors disclose no conflicts. Funding Information: Conflicts of interest These authors disclose the following: D. J. Lukin received consulting fees from AbbVie, Abgenomics, Pfizer, Prometheus, and Takeda, and grant support from AbbVie and Takeda . E. J. Scherl received grant support from AbbVie , AstraZeneca , Crohn’s and Colitis Foundation , Janssen , New York Crohn’s Foundation , Pfizer , UCB, Genentech , Seres Therapeutics, and Celgene , consulting fees from AbbVie, Abgenomics, Crohn’s and Colitis Foundation, Evidera, GI Health Foundation, Janssen, Protagonist, Seres, Takedal, stock from Gilead, and speaker for GI Health Foundation, Prime Therapeutics, and Janssen. R. S. Longman received grant support from Boehringer Ingelheim and consulting fees from Takeda, Pfizer, and Ancilla. The remaining authors disclose no conflicts.

PY - 2020/10

Y1 - 2020/10

KW - Biologic Therapy

KW - COVID-19

KW - IBD

KW - SARS-CoV-2

UR - http://www.scopus.com/inward/record.url?scp=85089150752&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2020.05.066

DO - 10.1053/j.gastro.2020.05.066

M3 - Article

C2 - 32479824

AN - SCOPUS:85089150752

SN - 0016-5085

VL - 159

SP - 1541-1544.e2

JO - Gastroenterology

JF - Gastroenterology

IS - 4

ER -